Literature DB >> 1315515

The catalytic subunit of protein kinase A triggers activation of the type V cyclic GMP-specific phosphodiesterase from guinea-pig lung.

F Burns1, I W Rodger, N J Pyne.   

Abstract

The type V cyclic GMP phosphodiesterase was partially purified from the high-speed supernatant of guinea-pig lung. The isoenzyme displayed linear kinetics for cyclic GMP hydrolysis, with Km = 2.2 +/- 0.2 microM and Vmax. = 1.2 +/- 0.08 nmol/min per mg. The selective type V phosphodiesterase inhibitor Zaprinast inhibited cyclic GMP hydrolysis with IC50 (concn. giving 50% inhibition) = 0.45 +/- 0.08 microM. Isobutylmethylxanthine promoted a 3-fold increase in the binding of cyclic GMP to the isoenzyme. The addition of the catalytic subunit of protein kinase A to an activation cocktail containing the partially purified type V phosphodiesterase resulted in a marked increase in Vmax. for cyclic GMP hydrolysis (approximately 10-fold at 40 units of protein kinase A). We have suggested that protein kinase A triggers phosphorylation of the phosphodiesterase, which results in activation of phosphodiesterase activity. In addition, the sensitivity to inhibition by Zaprinast is severely decreased (the IC50 for inhibition is 7.5 +/- 1.1 microM), suggesting that the potency of phosphodiesterase inhibitors is effected by phosphorylation of the enzyme.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1315515      PMCID: PMC1131061          DOI: 10.1042/bj2830487

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  Activation and phosphorylation of the 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase by cyclic AMP-dependent protein kinase.

Authors:  E Kilgour; N G Anderson; M D Houslay
Journal:  Biochem J       Date:  1989-05-15       Impact factor: 3.857

2.  Purification of cGMP-binding protein phosphodiesterase from rat lung.

Authors:  S H Francis; J D Corbin
Journal:  Methods Enzymol       Date:  1988       Impact factor: 1.600

3.  Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs.

Authors:  S A Harrison; D H Reifsnyder; B Gallis; G G Cadd; J A Beavo
Journal:  Mol Pharmacol       Date:  1986-05       Impact factor: 4.436

4.  Effect of insulin and lipolytic agents on rat adipocyte low Km cyclic adenosine 3':5'-monophosphate phosphodiesterase.

Authors:  B Zinman; C H Hollenberg
Journal:  J Biol Chem       Date:  1974-04-10       Impact factor: 5.157

5.  Multiple cyclic nucleotide phosphodiesterase activities from rat brain.

Authors:  W J Thompson; M M Appleman
Journal:  Biochemistry       Date:  1971-01-19       Impact factor: 3.162

6.  Phosphorylation results in activation of a cAMP phosphodiesterase in human platelets.

Authors:  C H Macphee; D H Reifsnyder; T A Moore; K M Lerea; J A Beavo
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

7.  Characterization of insulin-sensitive phosphodiesterase in fat cells. II. Comparison of enzyme activities stimulated by insulin and by isoproterenol.

Authors:  H Makino; T Kono
Journal:  J Biol Chem       Date:  1980-08-25       Impact factor: 5.157

8.  Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase.

Authors:  M K Thomas; S H Francis; J D Corbin
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

9.  Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP.

Authors:  M K Thomas; S H Francis; J D Corbin
Journal:  J Biol Chem       Date:  1990-09-05       Impact factor: 5.157

10.  Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine.

Authors:  J E Souness; R Brazdil; B K Diocee; R Jordan
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

View more
  7 in total

1.  Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle.

Authors:  K S Murthy
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

2.  Increased expression of the cGMP-inhibited cAMP-specific (PDE3) and cGMP binding cGMP-specific (PDE5) phosphodiesterases in models of pulmonary hypertension.

Authors:  Fiona Murray; Margaret R MacLean; Nigel J Pyne
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

3.  Role of cyclic nucleotides in vasodilations of the rat thoracic aorta induced by adenosine analogues.

Authors:  S M Hourani; K Boon; H M Fooks; D J Prentice
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation.

Authors:  I V Turko; S H Francis; J D Corbin
Journal:  Biochem J       Date:  1998-02-01       Impact factor: 3.857

5.  Modulation of the light response by cAMP in Drosophila photoreceptors.

Authors:  S Chyb; W Hevers; M Forte; W J Wolfgang; Z Selinger; R C Hardie
Journal:  J Neurosci       Date:  1999-10-15       Impact factor: 6.167

Review 6.  The role of protein phosphorylation in the regulation of cyclic nucleotide phosphodiesterases.

Authors:  J Beltman; W K Sonnenburg; J A Beavo
Journal:  Mol Cell Biochem       Date:  1993-11       Impact factor: 3.396

7.  Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries.

Authors:  Praveen Shukla; Chengwen Sun; Stephen T O'Rourke
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-10-19       Impact factor: 4.733

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.